Overview

  • Product name

    Lestaurtinib, JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor
  • Description

    Potent JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor
  • Biological description

    Potent JAK2, FLT3 and TrkA receptor tyrosine kinase inhibitor (IC50 values are 0.9, 3 and 25 nM respectively). Antiproliferative effects in vitro. Antileukemic agent in vivo. Orally active.
  • Purity

    > 98%
  • CAS Number

    111358-88-4
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Hexner EO  et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111:5663-71 (2008). Read more (PubMed: 17984313) »
  • Weisel KC  et al. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann N Y Acad Sci 1106:190-6 (2007). Read more (PubMed: 17442779) »
  • Miknyoczki SJ  et al. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci 880:252-62 (1999). Read more (PubMed: 10415871) »
See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142107.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up